Author

H. M. Froggatt

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Microbiology· 3

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 3 Research Focus:drug response / drug discovery· 2 Approach:experimental assay· 2 Assay:bulk RNA-seq· 1 Assay:fluorescence / live-cell microscopy· 1 Research Focus:gene regulatory network inference· 1 Approach:genetic perturbation / CRISPR· 1 Research Focus:host-pathogen & immune response· 1

Frequent Co-Authors

N. S. Heaton· 3 shared B. E. Heaton· 2 shared A. Jaochimiak· 1 shared A. T. Harding· 1 shared B. C. Dickinson· 1 shared B. C. Mounce· 1 shared B. Schuster· 1 shared C. B. Brooke· 1 shared

Activity by Year

2020-2020 · peak 3/yr

Co-Author Collaboration Network

10 top collaborators · 31 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersMicrobiology

N. S. Heaton

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Drug repurposing screen identifies masitinib as a 3CLpro inhibitor that blocks replication of SARS-CoV-2 in vitro

N. Drayman, K. A. Jones, S.-A. Azizi, H. M. Froggatt, K. Tan, N. Ivanova Maltseva, S. Chen, V. Nicolaescu, S. Dvorkin, K. Furlong, R. S. Kathayat, M. R. Firpo, V. Mastrodomenico, E. A. Bruce, M. M. Schmidt, , S. Tay

The paper screens 1,900 drugs to find inhibitors of SARS-CoV-2 replication, identifies masitinib as a 3CLpro inhibitor effective in vitro, and shows its broad anti-viral activity.

bioRxiv · Aug 31, 2020Microbiology

ETV7 limits antiviral gene expression and control of SARS-CoV-2 and influenza viruses

H. M. Froggatt, A. T. Harding, B. E. Heaton, N. S. Heaton

This study identifies ETV7 as a negative regulator of antiviral interferon-stimulated genes important for controlling influenza and SARS-CoV-2 infections.

bioRxiv · Jul 31, 2020 · PreprintMicrobiology

Development of a fluorescence based, high-throughput SARS-CoV-2 3CLpro reporter assay

H. M. Froggatt, B. E. Heaton, N. S. Heaton

This paper develops a fluorescence-based, high-throughput assay to screen for SARS-CoV-2 3CLpro inhibitors using a GFP-derived reporter that fluoresces after protease cleavage.

bioRxiv · Jun 24, 2020Microbiology